CD86 and histiocytic sarcoma: Finally, we tested the hypothesis whether canine histiocytic sarcoma (HS), a malignant canine tumor of interstitial DC origin that does not undergo regression but usually progresses with poor prognosis, lacks CD80 and CD86 expression.